Connect with us

News

Study: How long do the effects of cannabis last?

Published

on

Person driving a car
Researchers say findings raise questions about current drug-driving laws across the world

Researchers who evaluated how long someone is impaired after cannabis use, say their findings suggest current drug-driving laws may be “unjust”.

The new analysis from the Lambert Initiative at the University of Sydney in Australia, defines durations of impairment after inhaled or oral THC doses. 

The findings raise questions about current drug-driving laws across the world, which penalise for THC presence, not intoxication levels, researchers say.

A comprehensive analysis of 80 scientific studies has identified a ‘window of impairment’ of between three and 10 hours caused by moderate to high doses of the intoxicating component of cannabis, tetrahydrocannabinol (THC). 

The study found the exact duration of impairment depends on the dose of THC, whether the THC is inhaled or taken orally, whether the cannabis user is regular or occasional and the demands of the task being undertaken while intoxicated.

Published in Neuroscience & Biobehavioral Reviews, the study represents the first such meta-analysis and distilled the results of 80 separate scientific studies into THC-induced impairment conducted over the past 20 years. 

“Legal cannabis use, both medical and non-medical, is increasingly common across the world,” said lead author Dr Danielle McCartney from the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

“THC is known to acutely impair driving and cognitive performance but many users are unsure how long this impairment lasts and when they can resume safety-sensitive tasks, such as driving, after cannabis consumption.

“Our analysis indicates that impairment may last up to 10 hours if high doses of THC are consumed orally. A more typical duration of impairment, however, is four hours, when lower doses of THC are consumed via smoking or vaporisation and simpler tasks are undertaken (e.g., those using cognitive skills such as reaction time, sustained attention and working memory).

“This impairment may extend up to six or seven hours if higher doses of THC are inhaled and complex tasks, such as driving, are assessed.”

For this study a moderate THC dose is about 10mg, but researchers say what is moderate for a regular user could be high for those who only consume occasionally.

Co-author Dr Thomas Arkell, also from the Lambert Initiative, said: “We found that impairment is much more predictable in occasional cannabis users than regular cannabis users. Heavy users show significant tolerance to the effects of cannabis on driving and cognitive function, while typically displaying some impairment.”

The authors noted that regular users might consume more cannabis to achieve an effect, leading to an equivalent amount of impairment.

Many medicinal cannabis users consume THC in the form of oils, sprays or capsules and another important finding was that with such oral use the impairment takes longer to appear and lasts significantly longer than with inhaling.

Researchers said that the findings have implications for so-called drug-driving laws.

Academic director of the Lambert Initiative, Professor Iain McGregor, said: “THC can be detected in the body weeks after cannabis consumption while it is clear that impairment lasts for a much shorter period of time. Our legal frameworks probably need to catch up with that and, as with alcohol, focus on the interval when users are more of a risk to themselves and others. Prosecution solely on the basis of the presence of THC in blood or saliva is manifestly unjust.”

He added: “Laws should be about safety on the roads, not arbitrary punishment. Given that cannabis is legal in an increasing number of jurisdictions, we need an evidence-based approach to drug-driving laws.”

This paper follows recent research by Dr Arkell and colleagues that shows one of the medically active components of cannabis, cannabidiol (CBD) does not cause impairment in driving.

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.